Juian-Juian Fu
Dermatology · Henderson, NVNPI 1609866078
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 445 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 25.4% of the total. Reporting peaked in 2023 at $2,892 and has fallen 80.4% since, to $565 in 2025.
Across 445 payments — averaging $26.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Amgen$1K
- Regeneron Healthcare Solutions, Inc.$968
- Dermavant Sciences, Inc.$785
- Johnson & Johnson$713
- Pfizer$668
- plus $4K from 28 others
What the payments were for
- Food & beverage$11,22796%
- Education$4394%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 138 | $2,967 |
| Amgen(2 entities) | 44 | $1,223 |
| Regeneron Healthcare Solutions, Inc. | 22 | $968 |
| Dermavant Sciences, Inc. | 50 | $785 |
| Johnson & Johnson | 24 | $713 |
| Pfizer | 27 | $668 |
| Incyte Corporation | 12 | $424 |
| Galderma Laboratories, L.p. | 10 | $366 |
| Sun Pharmaceutical Industries Inc. | 15 | $337 |
| VYNE Pharmaceuticals Inc. | 4 | $328 |
| LEO Pharma Inc. | 18 | $328 |
| E.r. Squibb & Sons, L.L.C. | 14 | $292 |
| Bristol Myers Squibb | 12 | $289 |
| AstraZeneca(2 entities) | 2 | $243 |
| Biogen | 2 | $219 |
| Lilly USA, LLC | 8 | $199 |
| Sanofi | 5 | $187 |
| Arcutis Biotherapeutics, Inc. | 7 | $133 |
| UCB, Inc. | 1 | $125 |
| Novo Nordisk | 1 | $120 |
| Kyowa Kirin, Inc. | 1 | $119 |
| GSK | 1 | $119 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $100 |
| Almirall LLC | 4 | $80 |
| Novartis | 3 | $60 |
| Genentech USA, Inc. | 3 | $44 |
| EPI Health, LLC | 2 | $38 |
| Mayne Pharma Commercial LLC | 2 | $36 |
| Bioventus LLC | 1 | $34 |
| Journey Medical Corporation | 2 | $28 |
| Boehringer Ingelheim | 1 | $25 |
| Taro Pharmaceuticals USA, Inc. | 1 | $25 |
| Revance Therapeutics, Inc. | 1 | $25 |
| Organogenesis Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,666 in reported general payments places this provider in the 80th percentile of 78 dermatology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 25 | $128,517 |
| Dupixent PenDupilumab | 13 | $49,194 |
| EucrisaCrisaborole | 13 | $9,755 |
| Clobetasol Propionate | 45 | $2,096 |
| Metronidazole | 28 | $1,598 |
| Ketoconazole | 81 | $1,224 |
| Doxycycline Hyclate | 58 | $919 |
| Triamcinolone Acetonide | 127 | $899 |
| Clindamycin Phosphate | 18 | $765 |
| Imiquimod | 29 | $685 |
| Minoxidil | 58 | $591 |
| Azelaic Acid | 11 | $504 |
| Cephalexin | 19 | $322 |
| Mupirocin | 40 | $307 |
| Tretinoin | 14 | $282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $1,223 | $128,51725 claims |
| PfizerEucrisa | $668 | $9,75513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 78 dermatology providers in Nevada.
Other dermatology in Henderson
- Curt SamlaskaHenderson$101K
- Robert LiebermanHenderson$22K
- Cristian GonzalezHenderson$3K
- Daniel XieHenderson$2K
- David CotterLas Vegas$1.4M
- Harry GreenbergLas Vegas$1.1M
- Miriam BettencourtLas Vegas$772K
- Victoria FarleyLas Vegas$151K
- Laura OstezanReno$27K
- Linda WoodsonLas Vegas$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.